Gastrointestinal side effects are most prominent during this period, potentially contributing to decreased energy
The body needs to adjust to semaglutide Wegovys active ingredient, semaglutide, belongs to a family of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists)
Since very, very little of it makes it through the digestive system and into the bloodstream, a lot more needs to be given
Altered B12 handling and reduced clearance in kidney disease, and both cellular release and reduced clearance in liver disease, can raise B12, so supportive renal or hepatic findings make those causes plausible
This allows your provider to determine whether GLP-1 therapy may be appropriate based on your individual goals and health status
Frequently Asked Questions What exactly is Bioverse Review and how does it differ from Bioverse itself